Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

Official Title

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire

Brief Summary

      An open label, randomized controlled trial of single vs. multiple treatments of praziquantel
      in intestinal African schistosomiasis in Côte d'Ivoire

      This study aims to determine the efficacy of repeated (up to four times) praziquantel
      treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the
      traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive
      antigen- and DNA-detection methods.

Study Phase

Phase 3

Study Type


Primary Outcome

Cure rate

Secondary Outcome

 Reduction rates




4x Praziquantel

Study Arms / Comparison Groups

 Control group (A)
Description:  1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 1, 2018

Completion Date

January 14, 2019

Primary Completion Date

January 14, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at
             least one positive out of triplicate Kato-Katz thick smears)

          -  Subject is aged between 5 and 18 years and otherwise in good health

          -  Subject has received no recent praziquantel treatment in the past month

          -  Subject has provided oral assent and provided written informed consent signed by
             parents/legal guardian

          -  Subject is able and willing to provide multiple stool and urine samples during study

        Exclusion Criteria:

          -  Known allergy to study medication (i.e. praziquantel and albendazole)

          -  Pregnancy

          -  Lactating




5 Years - 18 Years

Accepts Healthy Volunteers



Jean Coulibaly, , 

Location Countries

Côte D'Ivoire

Location Countries

Côte D'Ivoire

Administrative Informations



Organization ID


Secondary IDs


Responsible Party

Principal Investigator

Study Sponsor

Leiden University Medical Center


 Swiss Tropical & Public Health Institute

Study Sponsor

Jean Coulibaly, Principal Investigator, Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

Verification Date

November 2020